3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
387
Colorectal Neoplasms
307
Rectal Neoplasms
225
Stomach Neoplasms
206
Pancreatic Neoplasms
137
Neoplasm Metastasis
121
Colonic Neoplasms
93
Neoplasms
85
Triple Negative Breast Neoplasms
63
Esophageal Neoplasms
57
Biliary Tract Neoplasms
37
Nasopharyngeal Carcinoma
36
Adenocarcinoma
31
Cholangiocarcinoma
30
Carcinoma, Hepatocellular
30
Gallbladder Neoplasms
28
Carcinoma, Non-Small-Cell Lung
21
Bile Duct Neoplasms
21
Locally Advanced Rectal Cancer
20
Adenocarcinoma Of Esophagus
20
Squamous Cell Carcinoma of Head and Neck
19
Gastrointestinal Neoplasms
18
Brain Neoplasms
18
Parkinson Disease 4, Autosomal Dominant Lewy Body
17
Liver Neoplasms
17
Head and Neck Neoplasms
17
Esophageal Squamous Cell Carcinoma
17
Ovarian Neoplasms
14
Colorectal Cancer Metastatic
14
Breast Neoplasms, Male
14
Interventions
camrelizumab
2
apatinib
2
Ramucirumab
2
trifluridine tipiracil drug combination
1
tipiracil
1
irinotecan sucrosofate
1
Trifluridine
1
S 1 (combination)
1
Fluorouracil
1
Docetaxel
1
Cisplatin
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Metastatic Gastric Adenocarcinoma
×
Capecitabine
×
Clear all
NCT02314117
2021-08-26
RAINFALL
Eli Lilly and Company
Phase 3
Completed
645 enrolled
22 charts